Evidence map›Paper›PMID 35739366›Full record

ArticleOral and maxillofacial surgery2023

Efficacy of fibrin-rich platelets and leukocytes (L-PRF) in tissue repair in surgical oral procedures in patients using zoledronic acid-case-control study.

Guilherme Klein Parise, Brenda Nazareth Costa, Miriã Lima Nogueira, Laurindo Moacir Sassi, Juliana Lucena Schussel

Open access · bronzeAbstract read
In one paragraph

Article in Oral and maxillofacial surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Guilherme Klein PariseDepartment of Stomatology, Post Graduate Program in Dentistry, Federal University of Paraná, Avenida Professor Lothário Meissner, 623, Jardim Botânico, Curitiba/PR, Brazil. guiparise@gmail.com.ORCID http://orcid.org/0000-0003-0417-9979
Brenda Nazareth CostaSchool of Dentistry, Federal University of Paraná, Curitiba, Brazil.
Miriã Lima NogueiraDepartment of Oral and Maxillofacial Surgery, Erasto Gaertner Hospital, Curitiba, Paraná, Brazil.
Laurindo Moacir SassiDepartment of Oral and Maxillofacial Surgery, Erasto Gaertner Hospital, Curitiba, Paraná, Brazil.
Juliana Lucena SchusselDepartment of Stomatology, Post Graduate Program in Dentistry, Federal University of Paraná, Avenida Professor Lothário Meissner, 623, Jardim Botânico, Curitiba/PR, Brazil.
Hospital Erasto Gaertner · BRInstituto de Pesquisas Jardim Botânico do Rio de Janeiro · BRUniversidade Federal do Paraná · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMedication-related osteonecrosis of the jaws (MRONJ) is a complication that develops in patients who use or have used antiresorptive or antiangiogenic medications for the treatment of bone metabolic disease and bone metastases. Clinically, MRONJ is characterized by the appearance of an inflammation in soft tissues and exposure of necrotic bone tissue in mandible or maxilla, for a period of 8 weeks, in patients with no history of head and neck radiotherapy that were being or are being treated with antiresorptive and/or antiangiogenic agents. The fibrin-rich platelets and leukocytes (L-PRF) membrane has been used as an alternative for MRONJ prevention. The aim of this study was to evaluate the use of L-PRF in prevention and treatment of bone necrosis. MATERIAL AND

methodsThe patients included had MRONJ diagnosis confirmed after clinical and radiographic examination and patients whose only therapeutic option was dental extraction.

resultsTwenty patients were included in the study and were divided in three groups. Two patients were removed from the study due to previous history of pentoxifylline and tocopherol use. The result of surgical treatment was successful in 57% in group 1 (control/MRONJ prevention), 100% in group 2 (MRONJ prevention), and 80% in group 3 (MRONJ treatment).

conclusionL-PRF is an autologous biomaterial that allows the release of growth factors for a prolonged time, resulting in a better healing, reducing the risk contamination, edema, and postoperative pain, being a great ally in the prevention and treatment of MRONJ because it returns to these patients, mainly quality of life, reducing pain, and recurrent infections commonly seen in the processes of bone necrosis of the jaws.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsPlatelet-Rich FibrinBlood PlateletsCase-Control StudiesDiphosphonatesFibrinHumansLeukocytesQuality of LifeZoledronic AcidBone Density Conservation AgentsDiphosphonatesFibrinZoledronic AcidBisphosphonate-associated osteonecrosis of the jawPlatelet-rich fibrinTreatment outcome

Identifiers

PMID35739366
PMCPMC9225877
OpenAlexW4283369125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.